Actinium Pharmaceuticals presented preclinical data at the 39th EANM Congress showing ATNM-400's effective antitumor activity in non-small cell lung cancer (NSCLC), colorectal, and ovarian cancer models. The therapy demonstrated potential both as a standalone treatment and in combination with existing therapies, including in resistant cancer models. These findings support ATNM-400's development as a mutation-agnostic targeted radiotherapy across multiple solid tumors, expanding its clinical potential beyond prostate cancer. The company plans to advance this therapy to address large patient populations with unmet medical needs.
Actinium Pharmaceuticals' recent presentations on ATNM-400 highlight its broad antitumor activity. For readers following the health sector, here is Pluang's market snapshot as of Oct 16, 2026 19:01 WIB: out of 150 priced health-sector US stocks tradable on Pluang, 93 rose and 46 fell. Notable movers include TLRY at USD 3.25 with a 1-day change of +1.25% and Pluang order activity showing 97% Sell, NUWE at USD 0.56 with a +1.23% change and nearly balanced buy/sell orders, and HNGE at USD 106.20 with a +1.18% change and a typical hold time of 1 day.
Nasdaq announced that trading in CN Healthy Food Tech Group Corp.'s common stock and warrants will resume on October 19, 2026, after being halted since October 1, 2025. The resumption marks the end of a year-long trading suspension, allowing investor...
David Solomon, CEO of Goldman Sachs, has been appointed as the new chair of The Business Council, taking over from Brian Cornell, Executive Chair of Target Corporation. This leadership change comes at a critical time as the Council addresses challeng...
SEDA Experts LLC has appointed Noor Ul Islam as Managing Director, enhancing its capabilities in risk management and securities practices. With nearly 30 years of experience at major financial institutions like Citibank and Barclays, Islam brings dee...
The global pharmaceutical market is projected to grow from USD 1.88 trillion in 2026 to USD 3.22 trillion by 2035, expanding at a CAGR of 6.15%. Growth is fueled by advances in biologics, AI-driven drug discovery, specialty drugs, and manufacturing i...
The Out of Home Advertising Association of America (OAAA) held the 84th Annual OBIE Awards in New York City, celebrating the best creative campaigns in out of home (OOH) advertising. Paramount was inducted into the OBIE Hall of Fame for its longstand...
